investment in cell therapies

Promising scale and market success for cell therapies after large financial injection

In a report released this week, by BCC Research, it was forecasted that the global market for stem cells (including cell therapies) is to reach US $10.6 billion in 2018. However with currently no medicines, based on stem cells, having yet received marketing authorisation from the EMA*, or the FDA*, how are we going to get there? In 2013, the stem cell …

stem cells

‘Manipulated’ Stem Cells: How iPSCs have gone from Nobel Prize research to novel therapy reality

First patient to receive induced pluripotent stem cells in Japan to treat macular degeneration – is this a result of their regulatory modifications?   2006 saw the discovery that normal human adult cells could be ‘reprogrammed’ to become stem cells that could adopt the form of any type of cell, from heart to liver to skin. Fast-forward to this decade …

Stem Cells Regenerative Medicine Congress is where experts like Advanced Cell Technology meet to network, learn from each other, and discuss the latest advances in regenerative medicine.

Advanced Cell Technology Shares Expertise on Advancing Toxicity and Safety Trials

Ted Myles, Chief Financial Officer and Executive Vice President of Corporate Development at Advanced Cell Technology, presented at the Stem Cells & Regenerative Medicine Congress in 2013. You can now download his presentation slides from the event, where he addresses advancing toxicity and safety trials to develop an effective macular degeneration cell-based therapy. You can view the recording of his …

Stem Cells Regenerative Medicine Congress is where experts like Neuralstem's Richard Garr meet to network, learn from each other, and discuss the latest stem cell strategies and technology.

Neuralstem’s Richard Garr on Optimizing and Increasing Titer

We were excited to have Richard Garr, Chief Executive Officer of Neuralstem, at last year’s Stem Cells Regenerative Medicine Congress. Richard gave a presentation on optimizing and increasing titer in early stage clinical trials for an easier approval process as part of the event that focused on next generation approaches. Other speakers that participated in that section of the event …

Download: Daratumumab, a novel therapeutic human CD38 monoclonal antibody – a promising new treatment option in multiple myeloma

Download this presentation here > The European Antibody Congress  brings together big pharma, big biotech, SME Biotech, academia, regulators and the wider service provider community to discuss the latest R&D and advances in the antibody space – across mAbs, ADCs, bispecifics, multispecifics, and protein scaffolds. At the 2013 event, delegates were fortunate enough to hear from Dr Michael Karl Bauer, Senior Vice President of …

Download: Clinical Development of Tanibirumab, anti-KDR neutralizing fully human IgG

Download this presentation here > The European Antibody Congress  brings together big pharma, big biotech, SME Biotech, academia, regulators and the wider service provider community to discuss the latest R&D and advances in the antibody space – across mAbs, ADCs, bispecifics, multispecifics, and protein scaffolds. At the 2013 event, delegates were fortunate enough to hear from Dr Jin-San Yoo, President and CEO, PharmAbcine Inc,  who …

Download: Biosimilar development, a CRO perspective

Download this presentation here > The World Biosimilar Congress  brings together pharma, biotech, academia and regulators and the wider service provider community to discuss the latest R&D, process, production, regulation and to-market strategies for biosimilar medicines. At the 2013 event, delegates were fortunate enough to hear from Dr John Patava, Director, Head Biosimilars Intelligence and Capabilities, Quintiles, who delivered the presentation ‘Biosimilar development, a CRO perspective‘. Download this presentation …

Download: Planning a clinical development program for biosimilars that meets the registration requirements of multiple regions

Download this presentation here > The World Biosimilar Congress  brings together pharma, biotech, academia and regulators and the wider service provider community to discuss the latest R&D, process, production, regulation and to-market strategies for biosimilar medicines. At the 2013 event, delegates were fortunate enough to hear from Hideaki Nomura, President and CEO, Fujifilm Kyowa Kirin Biologics Co Ltd, who delivered the presentation ‘Planning a clinical development program for …

antibodies

What are the antibodies to watch in 2014?

If you’re not sure, then Janice Reichert (Editor-in-Chief, mAbs Journal) has this covered. She’s written the handy report ‘Antibodies to watch in 2014‘ – this details all the monoclonal antibodies that are currently undergoing regulatory actions from the FDA and EMA, as well as details the  antibody therapeutics that are currently in Phase III trials. If you’re watching to see …

Video: Ted Harada on the ALS Patient Perspective on Stem Cells

Ted Harada sheds light on the patient perspective of stem cell treatments. Ted, who was diagnosed with Amyotrophic Lateral Sclerosis (ALS) in 2010, spoke at Stem Cells & Regenerative Medicine Congress 2013 of his own experience as a participant in stem cell clinical trials in a talk entitled ‘Ted’s ALS miracle – Inspiring hope in a fledgling industry.’ If you liked …